Skip to main content
Clinical Trials/EUCTR2014-005363-33-NL
EUCTR2014-005363-33-NL
Active, not recruiting
Phase 1

Reducing Micro Vascular dysfunction In revascularized STEMI patients by off-target properties of ticagrelor - REDUCE-MVI

VU university medical center0 sites110 target enrollmentApril 16, 2015

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
ST elevation myocardial infarction (STEMI)
Sponsor
VU university medical center
Enrollment
110
Status
Active, not recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 16, 2015
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional clinical trial of medicinal product

Investigators

Sponsor
VU university medical center

Eligibility Criteria

Inclusion Criteria

  • 1\.Provision of informed consent
  • 2\.Patients presenting with STEMI \<12 hours
  • 3\.Successful PCI of the infarct\-related vessel with a modern DES
  • 4\.Intermediate stenosis in non\-infarct\-related vessel (50\-90%)
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 70
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range 40

Exclusion Criteria

  • 1\.history of myocardial infarction
  • 2\.Participation in another clinical study with an investigational product during the preceding 30 days
  • 3\.history of cerebrovascular accident (CVA) or 'transient ischaemic attack' (TIA)
  • 4\.History of intracranial haemorrhage
  • 5\.indication or use of oral anticoagulant therapy (i.e. acenocoumarol)
  • 6\.severe liver dysfunction (Child\-Pughscore 10–15\)
  • 7\.congestive heart failure
  • 8\.cardiogenic shock
  • 9\.left ventricular ejection fraction \< 35%
  • 10\.bleeding diathesis

Outcomes

Primary Outcomes

Not specified

Similar Trials